Mistletoe and Gemcitabine in Patients with Advanced Cancer: A Model for the Phase I Study of Botanicals and Botanical-Drug Interactions in Cancer Therapy

Integrative Cancer Therapies

Volumn 2, Issue 4, 2003, Pages 345-352

  Mansky, Patrick J ^a   Grem, Jean ^b   Wallerstedt, Dawn B ^a   Monahan, Brian P ^c   Blackman, Marc R ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

Cancer; Clinical trial design; Mistletoe; Phase I study

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; CHLORPROPAMIDE; CYCLOSPORIN A; CYTOKINE; DRUG ANTIBODY; DRUG METABOLITE; GARLIC EXTRACT; GEMCITABINE; GINKGO BILOBA EXTRACT; GINSENG EXTRACT; HYPERICUM PERFORATUM EXTRACT; INDINAVIR; IRINOTECAN; KAVA EXTRACT; PARACETAMOL; PHENELZINE; PLANT EXTRACT; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT GAMMA INTERFERON; SIMVASTATIN; TACROLIMUS; THIAZIDE DIURETIC AGENT; TRAZODONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VISCOTOXIN; VISCUM ALBUM EXTRACT; VISCUM ALBUM LECTIN; VISCUM ALBUM LECTIN ANTIBODY; WARFARIN;

ADVANCED CANCER; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLOOD TOXICITY; BOTANY; BREAST CANCER; CANCER; CANCER CENTER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CREATININE BLOOD LEVEL; CYTOKINE RELEASE; DOSE CALCULATION; DRUG ACTIVITY; DRUG APPROVAL; DRUG CONTAMINATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG METABOLISM; DRUG QUALITY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; EOSINOPHILIA; EUROPE; FLU LIKE SYNDROME; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION; GERMANY; GINGIVITIS; GLIOMA; HEAD AND NECK CANCER; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOSTIMULATION; IN VIVO STUDY; MAXIMUM TOLERATED DOSE; MELANOMA; MODEL; NEUTROPHIL; OUTCOMES RESEARCH; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY CONTROL; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SOLID TUMOR; TREATMENT OUTCOME; UREA BLOOD LEVEL; VISCUM ALBUM;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE I; COMPLEMENTARY THERAPIES; DEOXYCYTIDINE; DRUG INTERACTIONS; HUMANS; MODELS, THEORETICAL; NEOPLASMS; PHYTOTHERAPY; PLANT EXTRACTS; PLANT PROTEINS; RESEARCH DESIGN; VISCUM ALBUM;

EID: 0344393561     PISSN: 15347354     EISSN: None     Source Type: Journal    
DOI: 10.1177/1534735403259061     Document Type: Review

References (74)

1. Steiner R. Geisteswissenschaft und Medizin. 6th ed. Dornach: Rudolf Steiner Verlag; 1985.
2. Kiene H. Klinische Studien zur Misteltherapie karzinomatoeser Erkrankungen, Eine Uebersicht. Therapeutikon. 1990;3:341-353.
3. Hauser SP. Iscador-Mistelpraeparat zur Krebsbekaempfung Dokumentation Nr. 10. Schweiz Rundschau Med Prax. 1988;77(4):69-74.
4. Kleijnen J, Knipschild P, Mistletoe treatment for cancer: review of controlled trials. Phytomedicine. 1994;1:255-260.
5. Grossarth-Maticek R, Kiene H, Baumgartner SM, Ziegler R. Use of Iscador, an extract of European mistletoe (Viscum album), in cancer treatment: prospective nonrandomized and randomized matched-pair studies nested within a cohort study. Altern Ther Health Med. 2001;7:57-66, 68-72, 74-56, passim.
6. Hostanska K, Hajto T, Spagnoli GC, Fischer J, Lentzen H, Herrmann R. A plant lectin derived from Viscum album induces cytokine gene expression and protein production in cultures of human peripheral blood mononuclear cells. Nat Immun. 1995;14:295-304.
7. Stein G, Berg PA. Non-lectin component in a fermented extract from Viscum album L. grown on pines induces proliferation of lymphocytes from healthy and allergic individuals in vitro. Eur J Clin Pharmacol 1994;47(1):33-38.
8. Rentea R, Lyon E, Hunter R. Biologic properties of Iscador: a Viscum album preparation I. Hyperplasia of the thymic cortex and accelerated regeneration of hematopoietic cells following X-irradiation. Lab Invest. 1981;44(1):43-48.
9. Beuth J, Ko HL, Tunggal L, et al. Thymocyte proliferation and maturation in response to galactoside-specific mistletoe lectin-1. In Vivo. 1993;7:407-410.
10. Kuttan G. Tumoricidal activity of mouse peritoneal macrophages treated with Viscum album extract. Immunol Invest. 1993;22:431-440.
11. Hamprecht K, Handgretinger R, Voetsch W, Anderer FA. Mediation of human NK-activity by components in extracts of Viscum album. Int J Immunopharmacol. 1987;9:199-209.
12. Hajto T, Lanzrein C. Natural killer and antibody-dependent cell-mediated cytotoxicity activities and large granular lymphocyte frequencies in Viscum album-treated breast cancer patients. Oncology. 1986;43:93-97.
13. Samtleben RHT, Hostanska K. Mistletoe lectins as immunostimulants (chemistry, pharmacology and clinic). In: Wagner H, ed. Immunomodulatory Agents From Plants. Basel, Switzerland: Birkhauser Verlag; 1999:223-241.
14. Lee RT, Gabius HJ, Lee YC. Ligand binding characteristics of the major mistletoe lectin. J Biol Chem. 1992;267:23722-23727.
15. Bussing A. Mistletoe therapy and immunological research. Anticancer Drugs. 1997;8(suppl 1):S65.
16. Stein GM, Berg PA. Mistletoe extract-induced effects on immunocompetent cells: in vitro studies. Anticancer Drugs. 1997; 8(suppl 1):S39-S42.
17. Gabius HJ, Andre S, Kaltner H, Siebert HC, von der Lieth CW, Gabius S. [The mistletoe myth - claims, reality and provable perspectives]. Z Arzil Fortbild (Jena). 1996;90:103-110.
18. Franz H. Mistletoe lectins and their A and B chains. Oncology. 1986;43(suppl 1):23-34.
19. Elsasser-Beile U, Voss M, Schuhle R, Wetterauer U. Biological effects of natural and recombinant mistletoe lectin and an aqueous mistletoe extract on human monocytes and lymphocytes in vitro. J Clin Lab Anal. 2000;14:255-259.
20. Elsasser-Beile U, Lusebrink S, Grussenmeyer T, Wetterauer U, Schultze-Seemann W. Comparison of the effects of various clinically applied mistletoe preparations on peripheral blood leukocytes. Arzneimittelforschung. 1998;48:1185-1189.
21. Ribereau-Gayon G, Dumont S, Muller C, Jung ML, Poindron P, Anton R. Mistletoe lectins I, II and III induce the production of cytokines by cultured human monocytes. Cancer Lett. 1996; 109(1-2):33-38.
22. Hajto T, Hostanska K, Weber K, et al. Effect of a recombinant lectin, Viscum album agglutinin on the secretion of interleukin-12 in cultured human peripheral blood mononuclear cells and on NK-cell-mediated cytotoxicity, of rat splenocytes in vitro and in vivo. Nat Immun. 1998;16(1):34-46.
23. Hajto T, Hostanska K, Frei K, Rordorf C, Gabius HJ. Increased secretion of tumor necrosis factors alpha, interleukin 1, and interleukin 6 by human mononuclear cells exposed to beta-galactoside-specific lectin from clinically applied mistletoe extract. Cancer Res. 1990;50:3322-3326.
24. Pae HO, Seo WG, Oh GS, et al. Potentiation of tumor necrosis factor-alpha-induced apoptosis by mistletoe lectin. Immunopharmacol Immunotoxicol. 2000;22:697-709.
25. Bussing A, Stein GM, Pfuller U, Schietzel M. Induction of Fas ligand (CD95L) by the toxic mistletoe lectins in human lymphocytes. Anticancer Res. 1999;19:1785-1790.
26. Kuttan G, Kuttan R. Reduction of leukopenia in mice by "viscum album" administration during radiation and chemotherapy. Tumori. 1993;79(1):74-76.
27. Weber K, Mengs U, Schwarz T, Becker H, Lentzen H. Stimulation of neutropoiesis by a special standardized mistletoe preparation after cyclophosphamide chemotherapy in mice. Arznieimittelforschung. 1996;46:1174-1178.
28. Savoie A, Lavastre V, Pelletier M, Hajto T, Hostanska K, Girard D. Activation of human neutrophils by the plant lectin Viscum album agglutinin-I: modulation of de novo protein synthesis and evidence that caspases are involved in induction of apoptosis. J Leukoc Biol. 2000;68:845-853.
29. Stettin A, Schultze JL, Stechemesser E, Berg PA. Anti-mistletoe lectin antibodies are produced in patients during therapy with an aqueous mistletoe extract derived from Viscum album L. and neutralize lectin-induced cytotoxicity in vitro. Klin Wochenschr. 1990;68:896-900.
30. Stein GM, Berg PA. Characterisation of immunological reactivity of patients with adverse effects during therapy with an aqueous mistletoe extract. Eur J Med Res. 1999;4:169-177.
31. Stein GM, Pfuller U, Berg PA. Recognition of different antigens of mistletoe extracts by anti-mistletoe lectin antibodies. Cancer Lett. 1999;135:165-170.
32. Lenartz D, Dott U, Menzel J, Schierholz JM, Beuth J. Survival of glioma patients after complementary treatment with galactoside-specific lectin from mistletoe. Anticancer Res. 2000;20:2073-2076.
33. Steuer-Vogt MK, Bonkowsky V, Ambrosch P, et al. The effect of an adjuvant mistletoe treatment programme in resected head and neck cancer patients: a randomised controlled clinical trial. Eur J Cancer 2001;37(1):23-31.
34. Eggermont AM KU, Ruiter DJ, Suciu S. European Organization of Research and Treatment of Cancer Melanoma Group trial experience with more than 2,000 patients, evaluating adjuvant treatment with low or intermediate doses of interferon alpha-2b. Paper presented at: American Society of Clinical Oncology Annual Meeting; 2001; San Francisco.
35. Heiny BM, Albrecht V, Beuth J. Correlation of immune cell activities and beta-endorphin release in breast carcinoma patients treated with galactose-specific lectin standardized mistletoe extract. Anticancer Res. 1998;18:583-586.
36. Heiny BM, Beuth J. Mistletoe extract standardized for the galactoside-specific lectin (ML-1) induces beta-endorphin release and immunopotentiation in breast cancer patients. Anticancer Res. 1994;14:1339-1342.
37. Friess H, Buchler M, Ebert M, Malfertheiner P, Dennler HJ, Beger HG. Treatment of advanced pancreatic cancer with high-dose octreotide. Int J Pancreatol. 1993;14:290-291.
38. Gorter RW, van Wely M, Reif M, Stoss M. Tolerability of an extract of European mistletoe among immunocompromised and healthy individuals. Altern. Ther Health Med. 1999;5(6):37-44, 47-38.
39. Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: a systematic review. Drugs. 2001;61:2163-2175.
40. Mathijssen RH, van Alphen RJ, Verweij J, et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res. 2001;7:2182-2194.
41. Harkey MR, Henderson GL, Gershwin ME, Stern JS, Hackman RM. Variability in commercial ginseng products: an analysis of 25 preparations. Am J Clin Nutr. 2001;73:1101-1106.
42. Liberti LE, Der Marderosian A. Evaluation of commercial ginseng products. J Pharm Sci. 1978;67:1487-1489.
43. Wurglics M, Westerhoff K, Kaunzinger A, et al. Comparison of German St. John's wort products according to hyperforin and total hypericin content. J Am Pharm Assoc (Wash). 2001; 41:560-566.
44. Edwards DJ, Draper EJ. Variations in alkaloid content of herbal products containing goldenseal. J Am Pharm Assoc (Wash DC). 2003;43:419-423.
45. Shohet D, Wills RB, Stuart DL. Valepotriates and valerenic acids in commercial preparations of valerian available in Australia. Pharmazie. 2001;56:860-863.
46. Bergonzi MC, Bilia AR, Gallori S, Guerrini D, Vincieri FF. Variability in the content of the constituents of Hypericum perforatum L. and some commercial extracts. Drug Dev Ind Pharm 2001;27:491-497.
47. Guns ES, Goldenberg SL, Brown PN. Mass spectral analysis of PC-SPES confirms the presence of diethylstilbestrol. Can J Urol. 2002;9:1684-1688; discussion, 1689.
48. White J. PC-SPES-a lesson for future dietary supplement research. J Natl Cancer Inst. 2002;94:1261-1263.
49. Laboratories LR. Gemcitabine hydrochloride LY 188011 Clinical Investigator's Brochure. Nov 3, 1994.
50. Kaye SB. Gemcitabine: current status of phase I and II trials. J Clin Oncol. 1994;12:1527-1531.
51. Lund B, Hansen OP, Theilade K, Hansen M, Neijt JP. Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst. 1994; 86:1530-1533.
52. Casper ES, Green MR, Kelsen DP, et al. Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs. 1994;12(1):29-34.
53. Abratt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D, Rugg TA. Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. J Clin Oncol. 1994; 12:1535-1540.
54. Rothenberg ML, Moore MJ, Cripps MC, et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol. 1996;7:347-353.
55. Stadler WM, Kuzel T, Roth B, Raghavan D, Dorr FA. Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol. 1997;15:3394-3398.
56. von Minckwitz G, Bauknecht T, Visseren-Grul CM, Neijt JP. Phase II study of gemcitabine in ovarian cancer. Ann Oncol. 1999;10:853-855.
57. Shapiro JD, Millward MJ, Rischin D, et al. Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Gynecol Oncol. 1996; 63(1):89-93.
58. Fossella FV, Lippman SM, Shin DM, et al. Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer. J Clin Oncol. 1997;15(1): 310-316.
59. Begbie SD, Hui R, Levi JA, et al. Initial experience with gemcitabine for non-small cell lung cancer in Australia. Proc Annu Meet Am Soc Clin Oncol. 1995;14:A1172.
60. Burris HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403-2413.
61. Blackstein M, Vogel CL, Ambinder R, Cowan J, Iglesias J, Melemed A. Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial. Oncology. 2002; 62(1):2-8.
62. Moore MJ, Tannock IF, Ernst DS, Huan S, Murray N. Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol. 1997;15:3441-3445.
63. Underhill CR, Parnis FX, Highley MS, et al. Multicenter phase II study of gemcitabine in previously untreated patients with advanced epithelial ovarian cancer. Anticancer Drugs. 2001;12: 647-652.
64. Goedhals L. BWR. A phase II study of gemcitabine in advanced cervix carcinoma: final data; 1996.
65. Abbruzzese JL, Grunewald R, Weeks EA, et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol. 1991;9:491-498.
66. Grunewald R, Kantarjian H, Du M, Faucher K, Tarassoff P, Plunkett W. Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study. J Clin Oncol. 1992; 10:406-413.
67. Lund B, Kristjansen PE, Hansen HH. Clinical and preclinical activity of 2′,2′-difluorodeoxycytidine (gemcitabine). Cancer Treat Rev. 1993;19:45-55.
68. Pollera CF, Ceribelli A, Crecco M, Calabresi F. Weekly gemcitabine in advanced or metastatic solid tumors. A clinical phase I study. Invest New Drugs. 1994;12:111-119.
69. Poplin EA, Corbett T, Flaherty L, et al. Difluorodeoxycytidine (dFdC)-gemcitabine: a phase I study. Invest New Drugs. 1992; 10:165-170.
70. Anderson H, Thatcher N, Walling J, Hansen H. A phase I study of a 24 hour infusion of gemcitabine in previously untreated patients with inoperable non-small-cell lung cancer. Br J Cancer. 1996;74:460-462.
71. Kassem B, Miketic LM, Landreneau RJ. Phase I study of gemcitabine given weekly as short infusion. Proc Am Soc Clin Oncol. 1995;14:383.
72. Martin C, Lund B, Anderson H, Thatcher N. Gemcitabine: once-weekly schedule active and better tolerated than twice-weekly schedule. Anticancer Drugs. 1996;7:351-357.
73. Touroutoglou N, Gravel D, Raber MN, Plunkett W, Abbruzzese JL. Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors. Ann Oncol. 1998;9:1003-1008.
74. 2) levels. Invest New Drugs. 1997;15:115-121.